Abstract
Recent studies have identified notable disparities in SARS-CoV-2 infection risk among ethnic minorities. We evaluated SARS-CoV-2 test results from individuals presenting for testing in Los Angeles between June-December, 2020. We calculated prevalence ratios for various employment categories. Among 518,914 test results, of which 295,295 (56.9%) were from individuals reporting Hispanic ethnicity, SARS-CoV-2 positivity was 16.5% among Hispanic individuals compared to 5.0% among non-Hispanic individuals (p-value<0.01). The prevalence ratios comparing Hispanic and non- Hispanic individuals was highest for members of the media (PR=6.7; 95% CI 4.3-10.4), government employees (PR=4.0; 95% CI 3.3-4.9), and agricultural workers (PR=4.0; 95% CI 3.2-5.0). Such heterogeneity warrants further investigation in order to develop targeted public health interventions towards specific drivers of SARS-CoV-2 transmission.
Competing Interest Statement
Dr. Allan-Blitz has served as a consultant for Curative Inc. Dr. Klausner has served as the medical director of Curative Inc. during the observation period. Fred Hertlein has served as an employee of Curative Inc. during the observation period.
Funding Statement
There was no funding for this project.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This article does not contain any studies with human participants performed by any of the authors. The Mass General Brigham institutional review board deemed the analysis of de-identified data did not constitute human subjects research (2020P003530).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data are available upon request.
